Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB for Hot Flashes in Prostate Cancer
NCT03796195Phase 4Terminated
- Sponsor
- Northwestern University
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bupivacaine in hot flashes, sponsored by Northwestern University. Primary endpoint: Hot Flash Frequency Change Baseline to 3 Months After Treatment. Started Nov 2019; status: terminated.
02
Drugs
bupivacaine
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT03796195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796195.